Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Jardiance Clear all
Active, not recruiting Phase 2Phase 3 Interventional Results available

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

NCT06149793
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Interventions
Empagliflozin, Placebo Control
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

NCT01289990
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Placebo, Sitagliptin 100mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

NCT01734785
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Empagliflozin + Linagliptin, Empagliflozin placebo + Linagliptin placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Gulf Shores, Alabama • Norwalk, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 9:52 AM EDT
Active, not recruiting Phase 1 Interventional

Effects of Acute and Chronic Empagliflozin Heart Failure

NCT05553938
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin 10 mg, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors

NCT05885074
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Empagliflozin Arm, Control Arm, Exercise capacity VO2 maximum determination, Exercise Challenge
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Antithrombotic Activities of Sotagliflozin vs. Empagliflozin

NCT06618976
View directory record Official record
Conditions
Thrombosis
Interventions
Sotagliflozin, Empagliflozin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

NCT01177813
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
27
States / cities
Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

NCT01867307
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Healthy
Interventions
Empagliflozin, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

NCT02106923
View directory record Official record
Conditions
Healthy
Interventions
1 tablet Empagliflozin/2 tablets Metformin XR, 10 mg Empagliflozin/1000 mg Metformin XR, 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR, 2 tablets 5 mg Empagliflozin/750 Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Dorzagliatin and Empagliflozin

NCT03790787
View directory record Official record
Conditions
Patients
Interventions
Empagliflozin, Dorzagliatin
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 21, 2026, 9:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

NCT05972564
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
Empagliflozin 25 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

NCT01422876
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
112
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 21, 2026, 9:52 AM EDT
Withdrawn Phase 3 Interventional

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

NCT06083675
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Empagliflozin, Metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 21, 2026, 9:52 AM EDT
Recruiting Phase 4 Interventional

Randomized Trial of SGLT2i in Heart Transplant Recipients

NCT06625073
View directory record Official record
Conditions
Heart Transplant, Cardiovascular Disease, Kidney Disease
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Palo Alto, California • Nashville, Tennessee • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Terminated Phase 2 Interventional

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

NCT06844669
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2+ Breast Cancer
Interventions
Carvedilol, Empagliflozin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 2 Interventional

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

NCT06926660
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vicadrostat, Empagliflozin, Placebo matching vicadrostat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Huntsville, Alabama • Anaheim, California • San Dimas, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Recruiting Phase 2 Interventional

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

NCT06992440
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Empagliflozin 10 MG, Placebo
Drug
Lead sponsor
Gustavo A Heresi, MD, MS
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

NCT01159600
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

NCT02863328
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, empagliflozin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Tuscumbia, Alabama • Encino, California • La Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 21, 2026, 9:52 AM EDT
Active, not recruiting No phase listed Observational

Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

NCT07188545
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome
Interventions
Intervention, Active Comparator
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23,280,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

NCT02414958
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Escondido, California • Huntington Beach, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 21, 2026, 9:52 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Neurovascular Effects of Empagliflozin

NCT07799441
View directory record Official record
Conditions
Blood Pressure, Endothelial Dysfunction
Interventions
Empagliflozin (EMPA), Placebo
Drug · Other
Lead sponsor
Kanokwan Bunsawat
Other
Eligibility
45 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Not yet recruiting Phase 2 Interventional

Vascular Effects of SGLT2i in Non-diabetic CKD

NCT07060417
View directory record Official record
Conditions
Non-diabetic Chronic Kidney Disease
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 9:52 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

NCT01210001
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
24
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 21, 2026, 9:52 AM EDT